These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26965919)

  • 1. Mutant calreticulin: when a chaperone becomes intrusive.
    Cazzola M
    Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
    Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
    Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant calreticulin in myeloproliferative neoplasms.
    How J; Hobbs GS; Mullally A
    Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Imai M; Araki M; Komatsu N
    Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
    Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
    Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
    Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
    Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
    Brooks SA; Kim DM; Morse SJ; Nguyen QH; Craver BM; Lai HY; Fleischman AG
    Leuk Res; 2019 Jul; 82():11-14. PubMed ID: 31128484
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
    Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
    Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Araki M; Yang Y; Imai M; Mizukami Y; Kihara Y; Sunami Y; Masubuchi N; Edahiro Y; Hironaka Y; Osaga S; Ohsaka A; Komatsu N
    Leukemia; 2019 Jan; 33(1):122-131. PubMed ID: 29946189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.
    Kramer F; Mullally A
    J Cell Mol Med; 2024 Mar; 28(5):e17896. PubMed ID: 37551061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
    Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
    Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications.
    Vainchenker W; Plo I; Marty C; Varghese LN; Constantinescu SN
    Expert Rev Hematol; 2019 Jun; 12(6):437-448. PubMed ID: 31092065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.